Molecular floats with CHF 482m market cap
Swiss venture capital-backed biotech Molecular Partners listed on the Swiss Exchange yesterday with a market cap of CHF 482m.
More on DACH
EQT Growth in active deployment with EUR 100m IntegrityNext deal
Sponsor to support organic growth of Munich-based ESG software group via inhouse digital and sustainability teams
European sponsors sidestep panic, concede gloom over bank woes
Fallout from Credit Suisse collapse adds to slew of macroeconomic challenges for PE dealmaking and fundraising
Deals face further financing uncertainty after Credit Suisse rescue
Delayed return of stabilized M&A conditions expected, advisors say; mid-cap transactions stand to fare best
Lenders sway fate of auctions in volatile LBO market
Vendors increasingly sounding out lenders before bidders to navigate uncertain M&A landscape
Latest News
GP Profile: Fortiland launches debut fundraise with ‘focus investing’ strategy
Sponsor is speaking to European professional investors and has a series of targets lined up, focusing on a single B2B distribution subsector in Italy
EQT Growth in active deployment with EUR 100m IntegrityNext deal
Sponsor to support organic growth of Munich-based ESG software group via inhouse digital and sustainability teams
MML buys majority stake in sponsor-backed Freeland
Existing investors IDI and Chevrillon will reinvest in the France-based freelance HR and IT platform as part of the SBO
Synova’s Clyde Munro exit parked in waiting room
Dental clinic sale could resume with improved macro conditions and after post-acquisition trasing plays out